Literature DB >> 27432073

Non-alcoholic fatty liver disease and risk of type 2 diabetes.

S Lallukka1, H Yki-Järvinen2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of liver disease from simple steatosis to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFLD is commonly associated with features of the metabolic/insulin resistance syndrome ('Metabolic/Obese NAFLD') and may therefore predict type 2 diabetes (T2DM). For this review, we searched for prospective studies examining whether NAFLD predicts T2DM, and if so, whether this occurs independently of factors such as age and obesity. These studies included NAFLD diagnosed by ultrasonography (n = 6) or liver enzymes (n = 14). All ultrasonography studies found NAFLD to predict the risk of T2DM independently of age, and in 4 out of 6 studies NAFLD was also a predictor independently of BMI. NAFLD was a predictor of T2DM in all 14 studies where NAFLD was diagnosed by liver enzymes. In 12 of these studies, ALT or AST or GGT were significant predictors of T2DM risk, independently of age and BMI. NAFLD, however, is heterogeneous and may also be caused by common genetic variants. The I148M variant in PNPLA3 and the E167K variant in TM6SF2 are both associated with increased liver fat content, but not features of the metabolic/insulin resistance syndrome. These genetic forms of NAFLD predict NASH and cirrhosis but not T2DM. Taken together these data imply that 'Metabolic/Obese NAFLD' predicts T2DM independently of age and obesity and support the role of hepatic insulin resistance in the pathogenesis of this disease.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  PNPLA3; TM6SF2; glucose; insulin; liver function tests; ultrasound

Mesh:

Substances:

Year:  2016        PMID: 27432073     DOI: 10.1016/j.beem.2016.06.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  48 in total

1.  Adipocyte JAK2 mediates growth hormone-induced hepatic insulin resistance.

Authors:  Kevin C Corbit; João Paulo G Camporez; Jennifer L Tran; Camella G Wilson; Dylan A Lowe; Sarah M Nordstrom; Kirthana Ganeshan; Rachel J Perry; Gerald I Shulman; Michael J Jurczak; Ethan J Weiss
Journal:  JCI Insight       Date:  2017-02-09

Review 2.  Metabolomics and Metabolic Diseases: Where Do We Stand?

Authors:  Christopher B Newgard
Journal:  Cell Metab       Date:  2016-10-27       Impact factor: 27.287

3.  The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases.

Authors:  Markku Laakso; Johanna Kuusisto; Alena Stančáková; Teemu Kuulasmaa; Päivi Pajukanta; Aldons J Lusis; Francis S Collins; Karen L Mohlke; Michael Boehnke
Journal:  J Lipid Res       Date:  2017-01-24       Impact factor: 5.922

Review 4.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

5.  Managing the Burden of Non-NASH NAFLD.

Authors:  Christopher J Danford; Jorge E Sanchez; Kathleen E Corey
Journal:  Curr Hepatol Rep       Date:  2017-10-27

6.  Aberrant gene expression induced by a high fat diet is linked to H3K9 acetylation in the promoter-proximal region.

Authors:  Núria Morral; Sheng Liu; Abass M Conteh; Xiaona Chu; Yue Wang; X Charlie Dong; Yunlong Liu; Amelia K Linnemann; Jun Wan
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2021-02-06       Impact factor: 4.490

7.  Dietary fatty acid oxidation is decreased in non-alcoholic fatty liver disease: A palmitate breath test study.

Authors:  Gihan Naguib; Nevitt Morris; Shanna Yang; Nancy Fryzek; Vanessa Haynes-Williams; Wen-Chun A Huang; Jaha Norman-Wheeler; Yaron Rotman
Journal:  Liver Int       Date:  2019-12-15       Impact factor: 8.754

8.  Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.

Authors:  Eiji Kutoh; Teruma Murayama; Asuka Wada; Mitsuru Hirate
Journal:  Drugs R D       Date:  2016-12

Review 9.  Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative.

Authors:  Maria de Fátima Brito; Carla Torre; Beatriz Silva-Lima
Journal:  Front Med (Lausanne)       Date:  2021-07-06

10.  Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China.

Authors:  Liwei Ji; Xintian Cai; Yang Bai; Tao Li
Journal:  Int J Gen Med       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.